News Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper Natalia Buendia CalvilloJune 5, 2023
Psychedelics Algernon partners with Yale University for phase II DMT study Algernon will provide cGMP DMT for the study in exchange for part-ownership of IP generated Rowan DunneOctober 24, 2022
Canada Algernon receives approval to conduct DMT study in the Netherlands New clinical research will assess efficacy of IV formulation for the treatment of strokes Rowan DunneSeptember 12, 2022